These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26589371)

  • 1. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD.
    Dajani AI; Abu Hammour AM; Zakaria MA; Al Jaberi MR; Nounou MA; Semrin AI
    Arab J Gastroenterol; 2015; 16(3-4):99-104. PubMed ID: 26589371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies.
    Ivashkin VT; Maevskaya MV; Shirokova EN; Maev IV; Samsonov AA; Sas EI; Palgova LK; Starostin K
    Drugs Real World Outcomes; 2021 Sep; 8(3):369-382. PubMed ID: 33993460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
    J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes.
    Targher G; Valbusa F; Bonapace S; Bertolini L; Zenari L; Pichiri I; Mantovani A; Zoppini G; Bonora E; Barbieri E; Byrne CD
    Nutr Metab Cardiovasc Dis; 2014 Jun; 24(6):663-9. PubMed ID: 24594085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes.
    Williams KH; Burns K; Constantino M; Shackel NA; Prakoso E; Wong J; Wu T; George J; McCaughan GW; Twigg SM
    J Diabetes Complications; 2015; 29(8):1240-7. PubMed ID: 26297218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management.
    Patel PJ; Hayward KL; Rudra R; Horsfall LU; Hossain F; Williams S; Johnson T; Brown NN; Saad N; Clouston AD; Stuart KA; Valery PC; Irvine KM; Russell AW; Powell EE
    Medicine (Baltimore); 2017 Jun; 96(26):e6761. PubMed ID: 28658094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Elastography efficiency in the liver fibrosis determination in patients with nonalcoholic fatty liver disease].
    Topil'skaia NV; Morozov SV; Isakov VA; Trufanova IuM; Kaganov BS
    Eksp Klin Gastroenterol; 2011; (6):26-31. PubMed ID: 22168074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis.
    Gaia S; Carenzi S; Barilli AL; Bugianesi E; Smedile A; Brunello F; Marzano A; Rizzetto M
    J Hepatol; 2011 Jan; 54(1):64-71. PubMed ID: 20932598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study.
    Honda Y; Kessoku T; Sumida Y; Kobayashi T; Kato T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Kataoka K; Taguri M; Yamanaka T; Seko Y; Tanaka S; Saito S; Ono M; Oeda S; Eguchi Y; Aoi W; Sato K; Itoh Y; Nakajima A
    BMC Gastroenterol; 2017 Aug; 17(1):96. PubMed ID: 28789631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
    Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
    Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).
    Kalra S; Vithalani M; Gulati G; Kulkarni CM; Kadam Y; Pallivathukkal J; Das B; Sahay R; Modi KD
    J Assoc Physicians India; 2013 Jul; 61(7):448-53. PubMed ID: 24772746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF; Sun Y; Shen L
    Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
    Williams CD; Stengel J; Asike MI; Torres DM; Shaw J; Contreras M; Landt CL; Harrison SA
    Gastroenterology; 2011 Jan; 140(1):124-31. PubMed ID: 20858492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Miyasato M; Murase-Mishiba Y; Bessho M; Miyawaki M; Imbe H; Tsutsumi C; Tanimoto K; Imagawa A; Terasaki J; Hanafusa T
    Clin Chim Acta; 2014 Jun; 433():184-9. PubMed ID: 24667697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement.
    Koot BG; van der Baan-Slootweg OH; Tamminga-Smeulders CL; Rijcken TH; Korevaar JC; van Aalderen WM; Jansen PL; Benninga MA
    Arch Dis Child; 2011 Jul; 96(7):669-74. PubMed ID: 21518734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
    Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease (NAFLD) without insulin resistance: Is it different?
    Singh SP; Misra B; Kar SK; Panigrahi MK; Misra D; Bhuyan P; Pattnaik K; Meher C; Agrawal O; Rout N; Swain M
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):482-8. PubMed ID: 25543522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis.
    Dajani AI; Popovic B
    World J Clin Cases; 2020 Nov; 8(21):5235-5249. PubMed ID: 33269259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.